Related Experiment Videos
Phospholipase A2 activating protein induces tumor regression.
D H Goddard1, J S Bomalaski, M A Clark
1Dept. of Medicine, Long Island College Hospital, Brooklyn, New York 11201, USA.
Drug News & Perspectives
|December 24, 2004
Summary
This study explores PLAP (placental alkaline phosphatase) as a novel cancer therapy. PLAP demonstrated significant tumor regression and increased survival in animal models, suggesting its potential in cancer treatment.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- The eicosanoid pathway and pro-inflammatory lipids modulate cancer growth.
- Inflammation and immune responses play roles in immune surveillance against tumors.
- Placental alkaline phosphatase (PLAP) is a pro-inflammatory agent with immune-modulating capacity.
Purpose of the Study:
- To investigate the potential of PLAP as a therapeutic agent for cancer.
- To explore the role of PLAP in cancer therapy by leveraging its pro-inflammatory and immune-modulating properties.
Main Methods:
- PLAP's pro-inflammatory properties were elucidated through various approaches.
- Tumor regression was assessed in an animal air pouch model of glioma after PLAP treatment.
- Life expectancy was evaluated in animal models with Lewis lung cancer and MTVL breast tumors treated with PEG-PLAP.
Main Results:
- A single PLAP treatment led to significant tumor regression in a glioma model within 72 hours.
- PEG-PLAP treatment increased the life expectancy of animals with Lewis lung cancer.
- Preliminary studies indicated a similar increase in life expectancy for mice with MTVL breast tumors treated with PLAP.
Conclusions:
- PLAP exhibits significant anti-tumor effects in preclinical models.
- PLAP demonstrates promise as a potential therapeutic agent for various cancers.
- Further research into PLAP for cancer therapy is warranted.